glp-1 drugs history Timeline of discovery and clinical development. (a) Key events in The expanding landscape of GLP-1

In the two-year STEP 5 study, 77.1% of participants lost at least 5% of their body weight , and 36.1% achieved a reduction of 20% or more

The receptor was pivotal to the ability to create long-lasting GLP-1 drugs for diabetes and obesity

10.1073/pnas.89.18.8641

Moreover, we retrieved other relevant records 56,57,58 : two large ( N = 133,318 and N = 342,608, respectively) cohort studies in people with diabetes across 613 years noted a beneficial association between GLP-1RA prescriptions compared with non-prescription and lower diagnoses of dementia 57,58 , while a small ( N = 154 patients with T2DM) and shorter (~12 months) cross-sectional investigation of GLP-1RAs in addition to metformin, compared with metformin alone, observed better MoCA scores in the former group 56